SINCO PHARMACEUTICALS HOLDINGS LIMITED |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.24 HKD | 0.00% |
|
+0.84% | 0.00% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 542.3 | 551.9 | 420.1 | 2,866 | 475.8 | 443.5 |
| Enterprise Value (EV) 1 | 590.8 | 514 | 358.4 | 2,881 | 339.1 | 256.9 |
| P/E ratio | -1.93 x | 24.1 x | 3.56 x | 19.8 x | 6.88 x | 10.5 x |
| Yield | - | - | - | - | 3.7% | 1.62% |
| Capitalization / Revenue | 0.57 x | 0.47 x | 0.2 x | 1.42 x | 0.21 x | 0.17 x |
| EV / Revenue | 0.62 x | 0.44 x | 0.17 x | 1.42 x | 0.15 x | 0.1 x |
| EV / EBITDA | -2.79 x | 7.22 x | 2.36 x | 14.6 x | 3.11 x | 2.02 x |
| EV / FCF | 1.5 x | -4.57 x | 4.39 x | -33.5 x | 5.87 x | 2.02 x |
| FCF Yield | 66.6% | -21.9% | 22.8% | -2.98% | 17.1% | 49.4% |
| Price to Book | 22.9 x | 11.9 x | 2.54 x | 7.69 x | 0.79 x | 0.71 x |
| Nbr of stocks (in thousands) | 1,691,891 | 1,691,891 | 1,691,891 | 1,860,891 | 2,032,891 | 2,032,891 |
| Reference price 2 | 0.3205 | 0.3262 | 0.2483 | 1.540 | 0.2340 | 0.2181 |
| Announcement Date | 4/22/19 | 5/5/20 | 4/20/21 | 4/8/22 | 4/25/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 953 | 1,176 | 2,050 | 2,024 | 2,272 | 2,540 |
| EBITDA 1 | -211.5 | 71.23 | 152 | 197.7 | 109 | 127.3 |
| EBIT 1 | -221.9 | 61.9 | 143.8 | 192.6 | 101.2 | 116.5 |
| Operating Margin | -23.28% | 5.26% | 7.01% | 9.51% | 4.46% | 4.58% |
| Earnings before Tax (EBT) 1 | -272 | 42.3 | 136 | 167.4 | 99.29 | 99.88 |
| Net income 1 | -280.6 | 22.9 | 118.1 | 135.1 | 69.46 | 42.35 |
| Net margin | -29.45% | 1.95% | 5.76% | 6.67% | 3.06% | 1.67% |
| EPS 2 | -0.1662 | 0.0135 | 0.0698 | 0.0778 | 0.0340 | 0.0208 |
| Free Cash Flow 1 | 393.3 | -112.4 | 81.61 | -85.98 | 57.81 | 126.9 |
| FCF margin | 41.27% | -9.56% | 3.98% | -4.25% | 2.54% | 5% |
| FCF Conversion (EBITDA) | - | - | 53.67% | - | 53.03% | 99.65% |
| FCF Conversion (Net income) | - | - | 69.08% | - | 83.22% | 299.62% |
| Dividend per Share | - | - | - | - | 0.008669 | 0.003540 |
| Announcement Date | 4/22/19 | 5/5/20 | 4/20/21 | 4/8/22 | 4/25/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 48.5 | - | - | 14.9 | - | - |
| Net Cash position 1 | - | 37.9 | 61.6 | - | 137 | 187 |
| Leverage (Debt/EBITDA) | -0.2294 x | - | - | 0.0753 x | - | - |
| Free Cash Flow 1 | 393 | -112 | 81.6 | -86 | 57.8 | 127 |
| ROE (net income / shareholders' equity) | -190% | 67% | 112% | 50.1% | 14.2% | 6.88% |
| ROA (Net income/ Total Assets) | -19.4% | 5.62% | 8.62% | 9.69% | 4.76% | 4.39% |
| Assets 1 | 1,448 | 407.2 | 1,370 | 1,395 | 1,459 | 964.5 |
| Book Value Per Share 2 | 0.0100 | 0.0300 | 0.1000 | 0.2000 | 0.3000 | 0.3100 |
| Cash Flow per Share 2 | 0.0500 | 0.1300 | 0.0800 | 0.1700 | 0.1600 | 0.2200 |
| Capex 1 | 1.15 | 0.56 | 0.37 | 23.5 | 52.7 | 29.6 |
| Capex / Sales | 0.12% | 0.05% | 0.02% | 1.16% | 2.32% | 1.16% |
| Announcement Date | 4/22/19 | 5/5/20 | 4/20/21 | 4/8/22 | 4/25/23 | 4/22/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| 0.00% | 62.42M | |
| +17.88% | 70.09B | |
| -1.07% | 24.01B | |
| +8.01% | 8.32B | |
| -18.28% | 8.23B | |
| +0.49% | 8.08B | |
| +4.40% | 4.68B | |
| +16.55% | 4.41B | |
| -0.70% | 4.12B | |
| -2.20% | 3.88B |
- Stock Market
- Equities
- 6833 Stock
- Financials Sinco Pharmaceuticals Holdings Limited